Allarity Therapeutics (ALLR) Expected to Announce Quarterly Earnings on Monday

Allarity Therapeutics (NASDAQ:ALLR) is expected to be issuing its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Allarity Therapeutics Price Performance

Shares of Allarity Therapeutics stock opened at $1.07 on Friday. Allarity Therapeutics has a 52 week low of $0.61 and a 52 week high of $2.35. The business has a 50 day moving average price of $1.05 and a 200-day moving average price of $1.23. The company has a market cap of $17.21 million, a PE ratio of -1.81 and a beta of 0.20.

Hedge Funds Weigh In On Allarity Therapeutics

Large investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of Allarity Therapeutics during the 4th quarter valued at approximately $36,000. DRW Securities LLC purchased a new position in Allarity Therapeutics in the 4th quarter valued at approximately $133,000. Renaissance Technologies LLC raised its holdings in Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock valued at $267,000 after acquiring an additional 181,426 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Allarity Therapeutics during the third quarter worth $149,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Allarity Therapeutics during the third quarter worth $441,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Ascendiant Capital Markets increased their target price on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Allarity Therapeutics has a consensus rating of “Hold” and an average target price of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.